Dr. James Ho
Pulmonologist, Clinical Associate Professor
Department of Medicine, University of
Hong Kong
-
Dec 2020
Digital Tools to Drive NGS Clinical Application for the Future
Explore the webinar series by clicking on the tabs
Explore the webinar series by selecting the dropdown
Various diagnostic tools play indispensable roles in diagnosing, staging, treatment selection & monitoring of lung cancer patients. This webinar shares multidisciplinary perspectives on 1) how diagnostics algorithms including biomarkers and other testing modalities influence decisions on targeted therapy selection; 2) how COVID has impacted management of oncology patients
Join our live webinar on 26th Aug to hear from a pulmonologist, Dr James Ho from the University of Hong Kong, a cardiothoracic surgeon, Dr Anand Sachithanandan from Sunway Medical Center Malaysia and a medical oncologist, Dr Takayuki Takahama from Kindai University Hospital Japan.
Chairman and Speaker |
||
|
 |
Chairman and SpeakerDr. James HoPulmonologist, Clinical Associate Professor
Department of Medicine, University of Hong
Kong |
Dr. James Ho is a Clinical Associate Professor at the Department of Medicine, The University of Hong Kong. He is a Specialist in Respiratory Medicine in Hong Kong, Fellow of the American College of Chest Physicians, Fellow of the Royal College of Physicians and Surgeons of Glasgow, Fellow of the Royal College of Physicians of Edinburgh and London. Dr. Ho has an established track record in lung cancer research, and the areas of focus over the years include the role of antioxidants, epidemiology, diagnostics, and management. The emphasis of recent projects is on translational research into novel lung cancer therapeutic options and clinical trials. Apart from being one of the pioneers in first-line systemic chemotherapy treatment for advanced Lymphoepithelioma-like carcinoma (LELC) of the lung, Dr. Ho and his team have reported insights into various multi-modal therapy options in lung cancer.
Speaker |
|
 |
Dr. Anand SachithanandanCardiothoracic Surgeon, Sunway Medical & Subang Jaya Medical
Centre |
Speaker |
|
|
Dr. Anand SachithanandanCardiothoracic Surgeon, Sunway Medical &
Subang Jaya Medical Centre Malaysia
|
Dr. Anand Sachithanandan is a consultant cardiothoracic surgeon in private practice in greater Kuala Lumpur with appointments at Sunway Medical & Subang Jaya Medical Centre Malaysia. He is a British board-certified cardiothoracic surgeon with specialist registration in both the United Kingdom (GMC) & Malaysia (MMC-NSR). He is a Fellow of the American College of Surgeons (F.A.C.S.), Royal College of Surgeons in Ireland (F.R.C.S.I.) and Royal College of Surgeons of Edinburgh (F.R.C.S.Ed). He is co-founder and president of Lung Cancer Network Malaysia, an NGO that aims to improve outcomes from lung cancer through awareness, advocacy and education
Speaker |
|
 |
Dr. Takayuki TakahamaMedical Oncologist Kindai Nara University Hospital |
|
SpeakerDr. Takayuki TakahamaMedical Oncologist Kindai Nara University Hospital Japan |
Takayuki Takahama M.D., Ph.D. is a lecturer at Kindai Nara university hospital, where he coordinates clinical trials and translational research, including systemic chemotherapy and genome biology. He is a board-certified doctor in medical oncology and respirology, and he graduated from Kindai University and has a Ph.D. He is specialized in genotyping with liquid samples in patients with lung cancer. So far, he led several translational research and investigator-initiated clinical trials to demonstrate the clinical utility of liquid biopsy and targeted therapy. He is the author of more than 10 articles in translational research. He can tell the usefulness and limitations of liquid biopsy.
EGFR is one of the most common mutations in NSCLC in Asian population. Several EGFR tyrosine kinase inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations . While tissue biopsy samples continue to be the gold standard, it is not feasible in all patients particularly when repeat biopsy is required. Liquid biopsy provides a non-invasive option for patients in order for them to access molecular testing.
Join our live webinar on 30th Oct to hear from Dr. Noemi Reguart, Medical Oncologist from Hospital Clinic Barcelona, Spain and Dr Kuo Chih-Hsi, Director of Thoracic Medicine at Medicine Chang Gung University Hospital in Taiwan.
Speaker |
|
 |
Dr. Noemi Reguart
Medical Oncologist Hospital |
Speaker |
|
|
Dr. Noemi ReguartMedical Oncologist Hospital |
Dr Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. Dr. Reguart has practiced as a Consultant Oncologist at the Department of Medical Oncology in Hospital Clinic Barcelona since 2008. She is a Clinical Professor at the University of Barcelona, deeply committed to under- and postgraduate teaching.
Throughout her career, Dr Reguart has shown her interest in addressing lung cancer. She has been involved in the design and patient recruitment to many personalised lung cancer trials. She has always maintained an active research interest in her own laboratory as well as through several national and international collaborations.
Speaker |
|
 |
Dr. Kuo Chih-HsiDirector of Department of Thoracic Medicine, |
Speaker |
|
|
Dr. Kuo Chih-HsiDirector of Department of Thoracic Medicine, |
Dr. Kuo Chih-Hsi is the Director of Department of Thoracic Medicine at Medicine Chang Gung University Hospital in Taiwan. Dr. Kuo has vast experience in clinical practice and hospital management and currently leading the department of attending doctors at the hospital.
Dr. Kuo Chih-Hsi completed his MD at Taipei Medical University in Taiwan and a fellowship in data science institute at Imperial College in London. Dr. Kuo’s primary interests are in Pulmonary Medicine, Interventional Bronchoscopy, Lung Cancer research. Dr. Kuo is also an active member in the Society of Internal Medicine, ROC , Taiwan Society of Pulmonary and Critical Care Medicine, and Taiwan Chest Disease Association. Dr. Kuo has published many research papers related to TKI and lung cancer and plays an active role in international medical affairs and is a regular speaker at ESMO ASIA and AZ events.
Moderator |
|
 |
Dr. Espen WalkerMedical and Scientific Affairs |
Moderator |
|
|
Dr. Espen WalkerMedical and Scientific Affairs |
Dr. Walker oversees medical affairs for the Roche oncology portfolio and NAVIFY in the Asia Pacific region, based in Singapore. Dr. Walker obtained his PhD in Biomedical Sciences in 2009 from the School of Medicine, University of New Mexico and postdoctoral fellowship in 2012 from University of California, San Francisco. He has been with Roche for nearly seven years and has been involved in the development and implementation of assays such as HER2 Dual ISH and PD-L1. Dr. Walker has a strong background in mechanistic pathology and biomarker identification including histological and molecular analysis of human cancer models, and characterization of pharmaceutical and antibody therapeutics. He has designed and developed many IVD products for cancer diagnostics. Recent work has been driving the oncology diagnostic precision medicine and the incorporation of digital tools such as NAVIFY into clinical oncology practice.
 |
Date:Friday, 30 Oct 2020 |
 |
|
Don’t worry, register now to view the recording after the event.
EGFR is one of the most common NSCLC mutations in the Asian population. Several EGFR Tyrosine Kinase Inhibitors (TKIs) are recommended by international guidelines as first-line treatment for patients with EGFR mutations. A robust and approved Companion Diagnostic (CDx) assay is preferred to properly identify eligible patients. With recent data in early-stage EGFR-positive NSCLC, there is an increase in therapy options and an increased value of diagnostics.
Join our live webinar on 7th Oct to hear from Dr. Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, Spain and Dr. Shanop Shuangshoti, Professor of Pathology at Chulalongkorn University, Thailand.
Speaker |
|
|
Dr. Noemi Reguart
Medical Oncologist Hospital |
Speaker |
|
|
Dr. Noemi ReguartMedical Oncologist Hospital |
Dr Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. Dr. Reguart has practiced as a Consultant Oncologist at the Department of Medical Oncology in Hospital Clinic Barcelona since 2008. She is a Clinical Professor at the University of Barcelona, deeply committed to under- and postgraduate teaching.
Throughout her career, Dr Reguart has shown her interest in addressing lung cancer. She has been involved in the design and patient recruitment to many personalised lung cancer trials. She has always maintained an active research interest in her own laboratory as well as through several national and international collaborations.
Speaker |
|
 |
Dr. Shanop ShuangshotiProfessor |
Speaker |
|
|
Dr. Shanop ShuangshotiProfessor |
Dr. Shanop Shuangshoti is affiliated to Pathology, Chulalongkorn University, where Dr. Shanop Shuangshoti is currently working as Professor. Dr. Shanop Shuangshoti has authored and co-authored several national and international publications and also working as a reviewer for reputed professional journals. Dr. Shanop Shuangshoti is having an active association with different societies and academies around the world.
Dr. Shanop Shuangshoti made his mark in the scientific community with the contributions and widely recognition from honourable subject experts around the world. Dr. Shanop Shuangshoti has received several awards for the contributions to the scientific community. His major research interest involves molecular diagnosis and neuropathology. Dr. Shanop Shuangshoti is currently Director of ChulaGenePRO Center, one of the well-known molecular diagnostic laboratories in Thailand.
Moderator |
|
|
Dr. Espen WalkerMedical and Scientific Affairs |
Moderator |
|
|
Dr. Espen WalkerMedical and Scientific Affairs |
Dr. Walker oversees medical affairs for the Roche oncology portfolio and NAVIFY in the Asia Pacific region, based in Singapore. Dr. Walker obtained his PhD in Biomedical Sciences in 2009 from the School of Medicine, University of New Mexico and postdoctoral fellowship in 2012 from University of California, San Francisco. He has been with Roche for nearly seven years and has been involved in the development and implementation of assays such as HER2 Dual ISH and PD-L1. Dr. Walker has a strong background in mechanistic pathology and biomarker identification including histological and molecular analysis of human cancer models, and characterization of pharmaceutical and antibody therapeutics. He has designed and developed many IVD products for cancer diagnostics. Recent work has been driving the oncology diagnostic precision medicine and the incorporation of digital tools such as NAVIFY into clinical oncology practice.
|
Date:Wednesday, 7th October 2020 |
|
|
Don’t worry, register now to view the recording after the event.
Lung cancer remains one of the most difficult-to-treat cancers. Treatment landscape of NSCLC has been evolving dramatically in the past ten years, and biomarker testing is becoming increasingly complex. Discussion between oncologists and pathologists plays an integral role in biomarker-driven therapy options to select the right patient for the right treatment at the right time. This webinar provides updates on treatment options in NSCLC, along with the oncology and pathology perspectives on molecular testing challenges and considerations in the clinical decision-making for lung cancer patients.
Join our live webinar on 13th Nov to hear from Prof Tony Mok chairman of the clinical oncology department at the Chinese University of Hong Kong and Prof Keith Kerr, a pathologist and chair of pulmonary pathology at the University of Aberdeen, Scotland.
Speaker |
||
|
 |
SpeakerProf. Tony MokChairman of the Department of Clinical Oncology, Chinese University of Hong Kong |
Professor Mok studied medicine and completed residency at the University of Alberta in Canada, and his fellowship training at Princess Margaret Hospital in Toronto. In 1996, Prof Mok moved to Hong Kong and gained Assistant Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, Prince of Wales Hospital. In 2007, he was made full Professor within the department plus attained an honorary professorship at the Guangdong Provincial People's Hospital, Guangdong, China and guest professorship at Peking University School of Oncology.
Professor Mok has published over 130 articles in international peer review journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology. He is the Associate Editor of the Journal of Thoracic Oncology, Clinical Lung Cancer and Asia Pacific Journal of Clinical Oncology and serves in the Editorial Board of Journal of Clinical Oncology and several other major oncology journals.
Prof. Mok is also actively involved in several professional societies and committees, including the Board of Directors of IASLC, chair of the International Affair Committee and member of publication committee of ASCO, vice secretary of the Chinese Society of Clinical Oncology and chairman of Hong Kong Cancer Therapy Society. He is also an ESMO Faculty Member with extensive presence at various international congresses and particularly interest in the application of novel therapeutic approaches in the treatment of lung and liver cancer.
Speaker |
|
 |
Prof. Keith KerrPathologist and Chair of Pulmonary |
Speaker |
|
|
Prof. Keith KerrPathologist and Chair of Pulmonary |
Prof. Keith Kerr graduated BSc with first class honors in Pathology in 1978, MB ChB in 1981, followed by post-graduate training in Pathology at Edinburgh University Medical School and the Royal Infirmary of Edinburgh. He obtained MRCPath in 1988, FRCPath in 1998 and was elected Honorary FRCP(Ed) in 2006. He has been a Consultant Pathologist in Aberdeen since 1989 and was awarded as Honorary Chair in Pulmonary Pathology by the University of Aberdeen in 2006.
Prof. Kerr has been a faculty of IASLC Pathology Panel, and participated in the 2004 IASLC/ASCO BAC workshop and 2011 IASLC/ATS/ERS Adenocarcinoma classification. He was panel member of the 2004 and 2015 WHO lung cancer classifications and International Mesothelioma Panel, and is currently involved in the revision of the CAP/IASLC/AMP guidelines for molecular pathology testing in lung cancer. Prof. Kerr is also a lead author of the ESMO Consensus Guidelines on pathology and molecular biomarkers for non-small-cell lung cancer.
Throughout more than 35 years in diagnostic histopathology, Prof. Kerr’s special interest is in Thoracic Pathology, with close links to clinical thoracic oncology practice. His research interests and international collaborations are in pulmonary pre-neoplasia and carcinogenesis, lung tumor diagnosis and classification and identification of predictors of therapy response.
Moderator |
|
|
Dr. Espen WalkerMedical and Scientific Affairs |
Moderator |
|
|
Dr. Espen WalkerMedical and Scientific Affairs |
Dr. Walker oversees medical affairs for the Roche oncology portfolio and NAVIFY in the Asia Pacific region, based in Singapore. Dr. Walker obtained his PhD in Biomedical Sciences in 2009 from the School of Medicine, University of New Mexico and postdoctoral fellowship in 2012 from University of California, San Francisco. He has been with Roche for nearly seven years and has been involved in the development and implementation of assays such as HER2 Dual ISH and PD-L1.
Dr. Walker has a strong background in mechanistic pathology and biomarker identification including histological and molecular analysis of human cancer models, and characterization of pharmaceutical and antibody therapeutics. He has designed and developed many IVD products for cancer diagnostics. Recent work has been driving the oncology diagnostic precision medicine and the incorporation of digital tools such as NAVIFY into clinical oncology practice.
|
Date:Friday, 13 th Nov 2020 |
|
|
Don’t worry, register now to view the recording after the event.
The amount of clinical data available for each patient has grown exponentially in the past decade. Clinicians are managing massive genomic information, histological analysis tools, and an explosion of clinical trials and publications. They must depend on connecting with other clinicians through multi-disciplinary tumour board meetings and digital tools to support decision making. This webinar will explore the potential of using digital clinical analysis and communication tools to help make optimal patient decisions.
Join our live webinar on the 12th Dec to hear from Assoc. Prof. Jason CH Hsieh, Medical Oncologist of the Tucheng Hospital and Chang Gung Memorial Hospital, Linkou, Taiwan and Assoc. Prof. Svetlana Cherepanoff, staff specialist anatomical pathologist at St Vincent’s Hospital, Australia.
Speaker |
||
|
 |
SpeakerAssoc. Prof. Jason CH HsiehMedical Oncologist, |
Assoc. Prof Jason CH Hsieh is a medical oncologist at Tucheng Hospital and Chang Gung Memorial Hospital in Linkou, Taiwan. His areas of focus are oncology and palliative care, with broad expertise in various cancer types. His research background includes design of microfluidic chips in three-dimensional cell culture. Recently, he has started to adopt digital tools in his institution to facilitate multi-disciplinary discussions with clinical decision support tools.
Speaker
|
|
 |
Assoc. Prof. Svetlana CherepanoffAnatomical Pathologist, |
Speaker
|
|
|
Assoc. Prof. Svetlana CherepanoffAnatomical Pathologist, |
Assoc. Prof. Svetlana Cherepanoff MBBS PhD FRCPA is a staff specialist anatomical pathologist at St Vincent’s Hospital, with an honorary academic appointment at the University of NSW. She is passionately committed to eye histopathology and cytopathology. She leads multi-institutional research projects in ocular oncology and retinal pathology.
Moderator |
|
|
Dr. Espen WalkerMedical and Scientific Affairs |
Moderator |
|
|
Dr. Espen WalkerMedical and Scientific Affairs |
Dr. Walker oversees medical affairs for the Roche oncology portfolio and NAVIFY in the Asia Pacific region, based in Singapore. Dr. Walker obtained his PhD in Biomedical Sciences in 2009 from the School of Medicine, University of New Mexico and postdoctoral fellowship in 2012 from University of California, San Francisco. He has been with Roche for nearly seven years and has been involved in the development and implementation of assays such as HER2 Dual ISH and PD-L1.
Dr. Walker has a strong background in mechanistic pathology and biomarker identification including histological and molecular analysis of human cancer models, and characterization of pharmaceutical and antibody therapeutics. He has designed and developed many IVD products for cancer diagnostics. Recent work has been driving the oncology diagnostic precision medicine and the incorporation of digital tools such as NAVIFY into clinical oncology practice.
|
Date:Saturday, 12th Dec 2020 |
|
|
Don’t worry, register now to view the recording after the event.
